Signals for B Cell Activation in Antibody Response
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Toll-Like Receptor 9 Signaling Acts on Multiple Elements of the Germinal Center to Enhance Antibody Responses
Toll-like receptor 9 signaling acts on multiple elements PNAS PLUS of the germinal center to enhance antibody responses Derek C. Rookhuizena,1 and Anthony L. DeFrancob,2 aDepartment of Molecular and Cell Biology, Life Sciences Addition, University of California, Berkeley, CA 94720; and bDepartment of Microbiology and Immunology, University of California, San Francisco, CA 94143 Edited by David Tarlinton, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia, and accepted by the Editorial Board June 24, 2014 (received for review December 23, 2013) Recent studies have demonstrated important roles of nucleic acid- where they provide survival and selection cues to antigen-pre- sensing Toll-like receptors (TLRs) in promoting protective antibody senting B cells through T-cell receptor (TCR) recognition of responses against several viruses. To dissect how recognition of antigenic peptide–MHC II complexes, costimulatory ligand– nucleic acids by TLRs enhances germinal center (GC) responses, receptor pairs, and cytokine production (8, 15, 16). Recently, + + mice selectively deleted for myeloid differentiation primary- it has become clear that some follicular CXCR5 CD4 T cells are + response protein 88 (MyD88) in B cells or dendritic cells (DCs) were thymically derived FoxP3 regulatory T cells, referred to as fol- immunized with a haptenated protein antigen bound to a TLR9 licular regulatory T (TFR) cells (17–22). Although their function ligand. TLR9 signaling in DCs led to greater numbers of follicular is poorly understood at this point, TFR cells appear to limit the helper T (TFH) cells and GC B cells, and accelerated production of size of the GC response (17–20). -
B Cell Immunity in Solid Organ Transplantation
REVIEW published: 10 January 2017 doi: 10.3389/fimmu.2016.00686 B Cell Immunity in Solid Organ Transplantation Gonca E. Karahan, Frans H. J. Claas and Sebastiaan Heidt* Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands The contribution of B cells to alloimmune responses is gradually being understood in more detail. We now know that B cells can perpetuate alloimmune responses in multiple ways: (i) differentiation into antibody-producing plasma cells; (ii) sustaining long-term humoral immune memory; (iii) serving as antigen-presenting cells; (iv) organizing the formation of tertiary lymphoid organs; and (v) secreting pro- as well as anti-inflammatory cytokines. The cross-talk between B cells and T cells in the course of immune responses forms the basis of these diverse functions. In the setting of organ transplantation, focus has gradually shifted from T cells to B cells, with an increased notion that B cells are more than mere precursors of antibody-producing plasma cells. In this review, we discuss the various roles of B cells in the generation of alloimmune responses beyond antibody production, as well as possibilities to specifically interfere with B cell activation. Keywords: HLA, donor-specific antibodies, antigen presentation, cognate T–B interactions, memory B cells, rejection Edited by: Narinder K. Mehra, INTRODUCTION All India Institute of Medical Sciences, India In the setting of organ transplantation, B cells are primarily known for their ability to differentiate Reviewed by: into long-lived plasma cells producing high affinity, class-switched alloantibodies. The detrimental Anat R. Tambur, role of pre-existing donor-reactive antibodies at time of transplantation was already described in Northwestern University, USA the 60s of the previous century in the form of hyperacute rejection (1). -
Extrafollicular Proliferation of B Cells in the Absence of Follicular Hyperplasia
Histopathology 2005, 47, 90–100. DOI: 10.1111/j.1365-2559.2005.02173.x Extrafollicular proliferation of B cells in the absence of follicular hyperplasia: a distinct reaction pattern in lymph nodes correlated with primary or recall type responses A Brighenti, M Andrulis,1 E Geissinger,1 S Roth,1 HKMu¨ller-Hermelink1 &TRu¨diger1 Istituto di Anatomia Patologica, Universita` degli Studi di Verona, Verona, Italy, and 1Institute of Pathology, University of Wu¨rzburg, Wu¨rzburg, Germany Date of submission 30 April 2004 Accepted for publication 10 March 2005 Brighenti A, Andrulis M, Geissinger E, Roth S, Mu¨ller-Hermelink H K & Ru¨diger T (2005) Histopathology 47, 90–100 Extrafollicular proliferation of B cells in the absence of follicular hyperplasia: a distinct reaction pattern in lymph nodes correlated to primary or recall type responses Aims: Extrafollicular activation of B cells is rarely cases proliferating cells were mainly IgG+CD27+, i.e. observed in human lymph nodes. The aim of this study derived from class-switched postgerminal centre mem- was to extensively analyse the expression of surface ory B cells. Some of these cells expressed CD30. In the molecules and transcription factors in four such cases, other two cases, immunoglobulin-forming cells were comparing them with follicular B cells and medullary non-class-switched IgM+CD27– B cells, representing a cord plasma cells. primary expansion of naive B cells. Methods and results: Various combinations of B-cell- Conclusions: Extrafollicular B-cell activation is the related surface markers and transcription factors were morphological correlate of rapid B-cell responses that studied by triple immunofluorescence. -
REVIEW Anti-CD20-Based Therapy of B Cell Lymphoma: State of The
Leukemia (2002) 16, 2004–2015 2002 Nature Publishing Group All rights reserved 0887-6924/02 $25.00 www.nature.com/leu REVIEW Anti-CD20-based therapy of B cell lymphoma: state of the art C Kosmas1, K Stamatopoulos2, N Stavroyianni2, N Tsavaris3 and T Papadaki4 1Department of Medicine, 2nd Division of Medical Oncology, ‘Metaxa’ Cancer Hospital, Piraeus, Greece; 2Department of Hematology, G Papanicolaou General Hospital, Thessaloniki, Greece; 3Oncology Unit, Department of Pathophysiology, Athens University School of Medicine, Laikon General Hospital, Athens, Greece; and 4Hemopathology Department, Evangelismos Hospital, Athens, Greece Over the last 5 years, studies applying the chimeric anti-CD20 ficulties in identifying a completely tumor-specific target; (2) MAb have renewed enthusiasm and triggered world-wide appli- the impracticality of constructing a unique antibody for each cation of anti-CD20 MAb-based therapies in B cell non-Hodg- kin’s lymphoma (NHL). Native chimeric anti-CD20 and isotope- patient; (3) the development of an immune response to murine 6 labeled murine anti-CD20 MAbs are currently employed with immunoglobulins (human anti-mouse antibodies, HAMA). By encouraging results as monotherapy or in combination with the end of the 1980s enthusiasm for therapeutic MAbs was conventional chemotherapy and in consolidation of remission waning; murine native (unconjugated), radioactively labeled after treatments with curative intent (ie after/ in combination or toxin-conjugated MAbs failed to yield significant clinical with high-dose chemotherapy and hematopoietic stem cell responses; moreover, they were not uncommonly associated rescue). On the available experience, anti-CD20 MAb-based therapeutic strategies will be increasingly integrated in the with toxicities, predominantly in the form of serum sickness treatment of B cell NHL and related malignancies. -
An Overview of B Cells – from Discovery to Therapy Mini Review
An Overview of B Cells – from Discovery to Therapy Mini Review Immunology In the past two decades, significant advances have been made in B cell biology. These critical immune cells remain an active area of research particularly because disruption of B cell development or function results in a number of autoimmune diseases and malignancies. In addition to producing antibodies, B cells are professional antigen presenting cells that can present antigens to T cells to generate effective immune responses. B cells are however, a heterogeneous population of cells at different stages of maturation along the lineage, each with unique functional properties. This mini-review provides a brief history of the discovery of B cells, as well as describes the characteristics of each B cell lineage and the processes of B cell development, maturation and activation. Finally, we highlight the application of B cell biology in the development of novel therapeutics for the treatment of B cell mediated diseases. Contents 1. A brief history of the discovery of B cells 2. B cell development and maturation 3. B cell activation and the humoral immune response 4. B cells as therapeutic targets 1. A brief history of the discovery of B cells B cells are an integral part of the adaptive immune response. They represent a distinct lineage, with separate and unique functions from T cells. In addition to producing antibodies, they perform critical immune functions such as generating immunological memory, antigen presentation and regulatory cytokine production. Our current understanding of B cell biology was initiated in 1965 with a landmark study by Max Cooper and Robert Good. -
Characterization of Intratumoral Follicular Helper T Cells in Follicular Lymphoma: Role in the Survival of Malignant B Cells
Leukemia (2012) 26, 1053 --1063 & 2012 Macmillan Publishers Limited All rights reserved 0887-6924/12 www.nature.com/leu ORIGINAL ARTICLE Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells P Ame´ -Thomas1,2,3,4,9, J Le Priol1,2,3,9, H Yssel5, G Caron1,2,3,4, C Pangault1,2,3,4, R Jean1,2,3,4, N Martin6,7, T Marafioti8, P Gaulard6,7, T Lamy1,2,3,4, T Fest1,2,3,4, G Semana1,2,3 and K Tarte1,2,3,4 Accumulating evidences indicate that the cellular and molecular microenvironment of follicular lymphoma (FL) has a key role in both lymphomagenesis and patient outcome. Malignant FL B cells are found admixed to specific stromal and immune cell pos subsets, in particular CD4 T cells displaying phenotypic features of follicular helper T cells (TFH). The goal of our study was to functionally characterize intratumoral CD4pos T cells. We showed that CXCR5hiICOShiCD4pos T cells sorted from FL biopsies comprise at least two separate cell populations with distinct genetic and functional features: (i) CD25pos follicular regulatory neg T cells (TFR), and (ii) CD25 TFH displaying a FL-B cell supportive activity without regulatory functions. Furthermore, despite their strong similarities with tonsil-derived TFH, purified FL-derived TFH displayed a specific gene expression profile including an overexpression of several genes potentially involved directly or indirectly in lymphomagenesis, in particular TNF, LTA, IL4 or CD40LG. Interestingly, we further demonstrated that these two last signals efficiently rescued malignant B cells from spontaneous and rituximab-induced apoptosis. -
The Bone Marrow Perisinusoidal Niche for Recirculating B Cells and the Positive Selection of Bone Marrow-Derived B Lymphocytes
Immunology and Cell Biology (2009) 87, 16–19 & 2009 Australasian Society for Immunology Inc. All rights reserved 0818-9641/09 $32.00 www.nature.com/icb REVIEW The bone marrow perisinusoidal niche for recirculating B cells and the positive selection of bone marrow-derived B lymphocytes Shiv Pillai and Annaiah Cariappa A unique ‘second’ niche for follicular B cells has been described in the extravascular compartment of the bone marrow surrounding vascular sinusoids. The occupancy of this niche by B cells presumably evolved to facilitate humoral immune responses to blood-borne pathogens. B cells appear to be sustained in this niche by bone marrow dendritic cells and are lost from this compartment in certain mutant mice. We discuss here what is known regarding the mechanisms of entry and egress of B cells from the perisinusoidal niche and also consider the function of the bone marrow as a secondary lymphoid organ. Although immature B cells can mature into follicular B cells in this niche as well as in the spleen, the lineage commitment event that accompanies positive selection of B cells occurs only in the spleen. Immunology and Cell Biology (2009) 87, 16–19; doi:10.1038/icb.2008.89; published online 25 November 2008 Keywords: perisinusoidal B cells; follicular B cells; positive selection; lymphocyte development; bone marrow; secondary lymphoid organ B cells in adult vertebrates develop initially in the bone marrow. About marrow.6 Although follicular B cells are supported in the conventional two-thirds of surface immunoglobulin M (IgM)-expressing immature follicular niche by follicular dendritic cells secreting the tumor B cells that have survived tolerance-related checkpoints exit the bone necrosis factor family member B cell activating factor of the TNF marrow and migrate to the spleen, whereas the remaining immature B family (BAFF), the survival of these very same B cells when they reside cells continue to mature in the bone marrow itself 1,2 (Figure 1). -
Molecular Genetics of B- and T Lymphocyte Development
UMEÅ UNIVERSITY MEDICAL DISSERTATIONS New series no.1030, ISSN 0346-6612, ISBN 91-7264-089-8 Molecular Genetics of B- and T Lymphocyte Development Ingela Wikström Department of Medical Biosciences Unit of Medical and Clinical Genetics Umeå University Sweden 2006 Department of Medical Biosciences Unit of Medical and Clinical Genetics Umeå University SE-901 85 Umeå, Sweden Copyright © 2006 by Ingela Wikström ISSN 0346-6612 ISBN 91-7264-089-8 Printed by Solfjädern Offset AB in Umeå, Sweden, 2006 2 Table of contents Abstract………….……………………………………………………………......................5 Abbreviations………………………………...……………………………………………...6 Articles……………………………………………………………………...……….………7 Introduction…………………………………………………………………………………8 1.1 The immune system…………………………………………...………………………...8 The non-specific immune system………………………………………………………...8 The specific immune system……………………………………………………………..8 1.2 Function of lymphocytes………………………………………………………………..9 B lymphocytes…………………………………………………………………………....9 T lymphocytes…………………………………………………………………………..13 1.3 Lymphocyte development……………………………………………………………..17 B cell development………………………………………………………………….…..17 T cell development……………………………………………………………………...21 2.1 Transcription factors controlling lymphocyte development….…………………….25 2.2 Basic helix-loop-helix transcription factors………………………………………….27 Structure, function and subclasses of bHLH proteins…………………………………..28 Regulation of E-protein activity………………………………………………………...30 E-proteins in B cell development……………………………………………………….31 E-proteins in T cell development………………………………………………………..35 -
Murine Norovirus Inhibits B Cell Development in Bone Marrow, but Does Not Impair Antibody
Murine norovirus inhibits B cell development in bone marrow, but does not impair antibody production in Stat1-/- mice Daniel Eldridge A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science University of Washington 2021 Reading Committee: Charlie C. Hsu Brian Iritani Jisun Paik Program Authorized to Offer Degree: Comparative Medicine © Copyright 2021 Daniel Eldridge University of Washington Abstract Murine norovirus inhibits B cell development in bone marrow, but does not impair antibody production in Stat1-/- mice Daniel Eldridge Chair of the Supervisory Committee: Charlie C. Hsu Department of Comparative Medicine Murine norovirus (MNV) is used as a model system to study human noroviruses, can infect macrophages/monocytes, neutrophils, dendritic, intestinal epithelial, T and B cells, and is highly prevalent in laboratory mice. We previously showed that MNV infection significantly reduces bone marrow B cell populations in a Stat1-dependent manner. We demonstrate here that while MNV-infected Stat1-/- mice have significant bone marrow B cell losses, expansion of splenic B cells capable of mounting an antibody response to novel antigens remains intact. We also investigated increased granulopoiesis as a mechanism of B cell loss, and we show that administration of anti-G-CSF antibody inhibits the pronounced bone marrow granulopoiesis induced by MNV infection of Stat1-/- mice, but this inhibition does not rescue bone marrow B cell losses. Therefore, these results show that MNV-infected Stat1-/- mice can still exhibit a robust humoral immune response in spite of decreased bone marrow B cells, and suggests that further investigation will be needed to identify other indirect factors or mechanisms that are responsible for the bone marrow B cell losses seen after MNV infection. -
Pools the Marginal Zone and Follicular B Cell IFN Regulatory
IFN Regulatory Factor 8 Restricts the Size of the Marginal Zone and Follicular B Cell Pools This information is current as Jianxun Feng, Hongsheng Wang, Dong-Mi Shin, Marek of September 24, 2021. Masiuk, Chen-Feng Qi and Herbert C. Morse III J Immunol 2011; 186:1458-1466; Prepublished online 22 December 2010; doi: 10.4049/jimmunol.1001950 http://www.jimmunol.org/content/186/3/1458 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2010/12/22/jimmunol.100195 Material 0.DC1 http://www.jimmunol.org/ References This article cites 48 articles, 31 of which you can access for free at: http://www.jimmunol.org/content/186/3/1458.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 24, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology IFN Regulatory Factor 8 Restricts the Size of the Marginal Zone and Follicular B Cell Pools Jianxun Feng,*,1 Hongsheng Wang,*,1 Dong-Mi Shin,* Marek Masiuk,*,† Chen-Feng Qi,* and Herbert C. -
Characterization of B Cell Development and Activation in the Absence of Akt Or Presenilin
University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Spring 2010 Characterization of B Cell Development and Activation in the Absence of Akt or Presenilin Marco Calamito University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Immunology and Infectious Disease Commons Recommended Citation Calamito, Marco, "Characterization of B Cell Development and Activation in the Absence of Akt or Presenilin" (2010). Publicly Accessible Penn Dissertations. 163. https://repository.upenn.edu/edissertations/163 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/163 For more information, please contact [email protected]. Characterization of B Cell Development and Activation in the Absence of Akt or Presenilin Abstract The biochemical pathways critical to B cell development remain poorly defined. Here I characterize a critical role for two separate families of proteins, Akt and Presenilin in the development and activation of B cells. The absence of Akt1 and Akt2 leads to a block in marginal zone (MZ) and B1B cell development, as well as decreased cellularity of splenic follicular B cells. In addition, I find the combined loss of Akt1 and Akt2 causes altered B cell receptor repertoire and poor competitive ability when matched against wild-type B cells. Similar to deficiencies in the Akt pathway the combined loss of Presenilin1 and Presenilin2 results in defective MZ, B1B cell development, and altered BCR repertoire selection. Furthermore, I find that these defects are independent of the Notch pathway and that Presenilins are required for optimal responses to cross-linking of the BCR. -
Igm Cellular Dynamics of Memory B Cell
Cellular Dynamics of Memory B Cell Populations: IgM + and IgG+ Memory B Cells Persist Indefinitely as Quiescent Cells This information is current as Derek D. Jones, Joel R. Wilmore and David Allman of September 24, 2021. J Immunol published online 5 October 2015 http://www.jimmunol.org/content/early/2015/10/03/jimmun ol.1501365 Downloaded from Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision http://www.jimmunol.org/ • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription by guest on September 24, 2021 Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published October 5, 2015, doi:10.4049/jimmunol.1501365 The Journal of Immunology Cellular Dynamics of Memory B Cell Populations: IgM+ and IgG+ Memory B Cells Persist Indefinitely as Quiescent Cells Derek D. Jones, Joel R. Wilmore, and David Allman Despite their critical role in long-term immunity, the life span of individual memory B cells remains poorly defined. Using a tet- racycline-regulated pulse-chase system, we measured population turnover rates and individual t1/2 of pre-established Ag-induced Ig class-switched and IgM-positive memory B cells over 402 d.